neurology

Biotech Adam Feuerstein

FDA agrees to review ALS treatment from Biogen, despite inconclusive clinical trial results

Biotech Adam Feuerstein

FDA to convene second panel of outside experts to review Amylyx Pharma’s ALS treatment

Biotech Ryan Cross — The Boston Globe

Can Biogen’s backup plan for Alzheimer’s succeed?

Health Tech Mario Aguilar

Cognito Therapeutics raises $50 million for Alzheimer’s treatment tech

First Opinion Cecille Joan Avila

The often-overlooked connection between traumatic brain injury and domestic violence

In the Lab Jonathan Wosen

The brain ‘learns’ to have seizures more efficiently and frequently over time, mouse study shows

First Opinion Bernard Zipprich

Will the shadow of Aduhelm cloud FDA’s decision-making on an ALS therapy?

The Pharmalot View Ed Silverman

‘Precedents are important’: Aduhelm coverage restrictions could shape the future of accelerated approval

Health Tech Katie Palmer

With pharma still struggling in Alzheimer’s, health tech companies want a swing

In the Lab Meghana Keshavan

With new ‘brain-reading’ research, a once-tarnished scientist seeks redemption

D.C. Diagnosis Nicholas Florko

Before Aduhelm, Billy Dunn was a superstar at the FDA

Politics Nicholas Florko

An ALS therapy sets up a crucial test of the FDA’s independence

Video Chat Gideon Gil

Virtual Event – ‘Augmented’: The future of brain-controlled prosthetic limbs

In the Lab Jonathan Wosen

Scientists take key step toward unraveling the genetic roots of ALS in a pair of studies

Special Report Isabella Cueto

Jolting the brain’s circuits with electricity is moving from radical to almost mainstream therapy. Some crucial hurdles remain

Pharmalot Ed Silverman

A looming decision on Medicare coverage for Biogen’s Alzheimer’s drug could shock state Medicaid programs

Biotech Maaisha Osman

4 epilepsy-focused biotech companies to watch

Exclusive Kate Sheridan

Flagship to launch a new startup focused on neurodegenerative conditions, including Parkinson’s

Biotech Matthew Herper

Acadia drug meets endpoints for treating Rett syndrome, a rare neurological disease

Biotech Damian Garde

Cortexyme bets a lower dose of its once-failed Alzheimer’s drug can work in another trial

In the Lab Elizabeth Cooney

New study revives a Mozart sonata as a potential epilepsy therapy

The Pharmalot View Ed Silverman

‘Remember her as the badass she was’: ALS patient who died should force Biogen, others to anticipate expanded access issues

Pharmalot Ed Silverman and Damian Garde

Veterans Affairs declines to cover Biogen’s Alzheimer’s drug over effectiveness, safety concerns

Biotech Joanne Silberner

Accelerated approval, the path used to greenlight Biogen Alzheimer’s drug, has a checkered track record, critics say

Pharmalot Ed Silverman

Expert panel votes unanimously that Biogen Alzheimer’s drug doesn’t offer patient benefits